jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Mar. 20, 2019

June. 20, 2024

jRCTs071180067

Clinical research for safty and efficacy in intralesional sclerotherapy with ethanolamine oleate for subcutaneous venous malformation in the oral and maxillofacial region (EOST-OMS)

Clinical research of intralesional sclerotherapy in the oral and maxillofacial region (ST-OMS)

Danjo Atsushi

Saga University

5-1-1, Nabeshima, Saga-City, Saga, Japan

+81-952-34-2397

danjoat@cc.saga-u.ac.jp

Aijima Reona

Saga University

5-1-1, Nabeshima, Saga-City, Saga, Japan

+81-952-34-2397

f8197@cc.saga-u.ac.jp

Recruiting

Aug. 03, 2009

Oct. 23, 2009
25

Interventional

single arm study

open(masking not used)

no treatment control/standard of care control

factorial assignment

treatment purpose

1. Venous malformation in the oral and maxillofacial region
2. Low-flow venous malformation diagnosed in contrasted MRI or CT
3. Both gender, any age
4. Written informed consent (<20 patients; Written informed consent by guardians)

1. 24hCCr<70L/day or Creatinine Clearance estimate <60 ml/min
2. Unfit for the clinical research
3. Uncooperative for the treatments under local anesthesia

No limit
No limit

Both

Venous malformation in the oral and maxillofacial region

Single arm study, open (masking not used), no assignment
All procedures will be done with oral surgeon and radiologist in angiography room. (For superficial lesion, procedures will be done with intermittent simple X-ray for reduction of exposure, despite using angiography to confirm drainage veins in oral and maxillofacial outpatient clinic.)
1. Local anesthesia into the lesion.
2. Puncture with 22-24G needle and confirm the backflow of blood.
3. Stabilize the needle and check the distribution and blood flow of the lesion by angiography and computed tomography (CT) with contrast medium. If there is any risk that sclerosing agent will escape whole body, we must decide the cancellation of the trial. If we can block the drainage vein over 5 minutes, we decide that the trial can continue. (For superficial lesions, we inject contrast medium in oral and maxillofacial outpatient clinic and confirm retention of contrast medium using intermittent simple X-ray.)
4. Treat with injection 5% ethanolamine oleate(EO) (diluted by Iopamiron 300) . Volume of the 5%EO will be decided by situation, but the maximum volume is 20ml (5% EO) by one treatment. After 5 minites, the 5%EO collect as possible.
5. Check the hemostasis of the injection point(s).

Sclerotherapy, Venous malformation, ethanolamine oleate

angioma, venous

sclerotherapy

Reduction rate

Adverse events: rate, details, severity, recurrence rate

Saga University Clinical Research Review Board
5-1-1, Nabeshima, Saga-City, Saga, Japan, Saga

+81-952-34-3357

crb@mail.admin.saga-u.ac.jp
Approval

Mar. 06, 2019

No

none

History of Changes

No Publication date
5 June. 20, 2024 (this page) Changes
4 July. 01, 2022 Detail Changes
3 June. 21, 2022 Detail Changes
2 May. 20, 2021 Detail Changes
1 Mar. 20, 2019 Detail